Skip Nav Destination
Issues
1 September 2015
-
Cover Image
Cover Image
SIRT3, a member of the sirtuin family of protein deacetylases, prevents cell aging by enhancing metabolic homeostasis through regulation of mitochondrial protein deacetylation. How it functions in tumor response to anticancer therapy is unknown. Liu and colleagues discovered that SIRT3 was transcriptionally regulated by NF-kB upon radiation, and its enzymatic activity was further enhanced via phosphorylation also by mitochondria-localized Cyclin B1/CDK1 complex. The phosphorylation of SIRT3 by CDK1 was required for mitochondrial functions as well as for cell survival tested by in vitro and in vivo radiation. Thus, targeting CDK1-SIRT3 phosphorylation-mediated mitochondrial metabolism provides an alternative approach to enhance tumor response to radiotherapy. For details, see the article by Liu and colleagues on page 2090. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
Christopher T. Cummings; Weihe Zhang; Kurtis D. Davies; Gregory D. Kirkpatrick; Dehui Zhang; Deborah DeRyckere; Xiaodong Wang; Stephen V. Frye; H. Shelton Earp; Douglas K. Graham
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
Bryan D. Smith; Michael D. Kaufman; Cynthia B. Leary; Benjamin A. Turner; Scott C. Wise; Yu Mi Ahn; R. John Booth; Timothy M. Caldwell; Carol L. Ensinger; Molly M. Hood; Wei-Ping Lu; Tristan W. Patt; William C. Patt; Thomas J. Rutkoski; Thiwanka Samarakoon; Hanumaiah Telikepalli; Lakshminarayana Vogeti; Subha Vogeti; Karen M. Yates; Lawrence Chun; Lance J. Stewart; Michael Clare; Daniel L. Flynn
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Ricardo Ribas; Sunil Pancholi; Stephanie K. Guest; Elisabetta Marangoni; Qiong Gao; Aurélie Thuleau; Nikiana Simigdala; Urszula M. Polanska; Hayley Campbell; Aradhana Rani; Gianmaria Liccardi; Stephen Johnston; Barry R. Davies; Mitch Dowsett; Lesley-Ann Martin
Large Molecule Therapeutics
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Elena Geretti; Shannon Curtis Leonard; Nancy Dumont; Helen Lee; Jinzi Zheng; Raquel De Souza; Daniel F. Gaddy; Christopher W. Espelin; David A. Jaffray; Victor Moyo; Ulrik B. Nielsen; Thomas J. Wickham; Bart S. Hendriks
Cancer Biology and Signal Transduction
CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Rui Liu; Ming Fan; Demet Candas; Lili Qin; Xiaodi Zhang; Angela Eldridge; June X. Zou; Tieqiao Zhang; Shuaib Juma; Cuihong Jin; Robert F. Li; Julian Perks; Lun-Quan Sun; Andrew T.M. Vaughan; Chun-Xu Hai; David R. Gius; Jian Jian Li
Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Sandra N. Freiberger; Phil F. Cheng; Guergana Iotzova-Weiss; Johannes Neu; Qinxiu Liu; Piotr Dziunycz; John R. Zibert; Reinhard Dummer; Kresten Skak; Mitchell P. Levesque; Günther F.L. Hofbauer
Models and Technologies
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.